INV 12 Surgical approach on melanoma patients: an EORTC melanoma group survey

Testori, Alessandro; Soteldo, Javier; Sales, F.; Borgognoni, Lorenzo; Nowecki, Zbigniew; Lejeune, Ferdy J.; Stoitchkov, Konstantin; Eggermont, Alexander; Powell, Barry

doi:10.1097/00008390-200702000-00022

Cited by 7 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Electroporation (EP) or the drugs on their own do not influence the growth of tumors, but the combination of the EP and bleomycin has potent antitumor effects. In previous reports, ECT has shown to be effective as palliative treatment of cutaneous and subcutaneous metastases in patients with cutaneous melanoma [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28].…”

Section: Discussionmentioning

confidence: 99%

Electrochemotherapy in Melanoma Patients: A Single Institution Experience

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Electrochemotherapy in Melanoma Patients: A Single Institution Experience

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Several trials have shown no survival benefit to performing elective lymph node dissections if regional LNs are not known to harbor metastatic disease. As such, precise identification of draining sentinel lymph nodes (SLN) and removal of basins involved with tumor are of paramount importance in disease control.…”

Section: Introductionmentioning

confidence: 99%

“…2,3 The presence of nodal metastases is the most important prognostic factor in cutaneous melanoma, 4 and the number of nodes involved is also highly correlated with prognosis among patients with metastases to regional LN. 5 Several trials 2,6 have shown no survival benefit to performing elective lymph node dissections if regional LNs are not known to harbor metastatic disease. As such, precise identification of draining sentinel lymph nodes (SLN) and removal of basins involved with tumor are of paramount importance in disease control.…”

Section: Introductionmentioning

confidence: 99%

Contrast‐Enhanced Ultrasound With Perflubutane for Sentinel Lymph Node Mapping in Cutaneous Melanoma: A Pilot Study

Bertelsen¹,

King

Swanson³

et al. 2018

The Laryngoscope

View full text Add to dashboard Cite

Objective To study the feasibility of contrast‐enhanced ultrasound (CEUS) for identification of SLN associated with cutaneous melanoma. Study Design Single arm pilot study in a swine animal model. Methods One milliliter of perflubutane (Sonazoid, GE Healthcare, Milwaukee, WI) was injected into the peritumoral dermis in five swine with cutaneous melanoma. Ultrasonography was used to follow enhancing lymphatic channels to lymph nodes (LN). Intradermal injection of vital blue (VB) dye was used as a positive control. LN identified by either method were excised and examined histologically. Results There were five primary cutaneous melanomas with mean area of 4.36 ± 4.75 cm2 and Breslow depth of 3.6 ± 1.5 mm. Six possible sentinel lymph node (SLN)s were identified with CEUS, and nine were identified with VB. SLN averaged 12.44 ± 6.15 cm from the primary tumor. Four of six (67%) SLNs identified by CEUS and four of nine (44%) candidate SLNs identified by VB contained histologically confirmed metastatic melanoma. All six CEUS‐identified SLNs were also identified with VB. Two LNs not containing melanoma were identified by CEUS; three were identified with VB. In all SLN with metastases, metastatic cells were scattered throughout the LN and not clustered in a discrete mass. Conclusion CEUS with perflubutane feasibly identifies SLN associated with cutaneous melanoma and may be a useful adjunct technology in facilitating precise SLN dissection. Our work supports a clinical trial investigating the use of CEUS for this application. Level of Evidence NA Laryngoscope, 129:1117–1122, 2019

show abstract

“…A standard operating procedure (SOP) for ECT was issued in 2006, as a milestone for the technology 16 . This undoubtedly increased the usage of ECT in clinics, especially in the European Union 17 . In 2012, more than 3,000 patients were treated with ECT in the European Union 18 .…”

Section: Introductionmentioning

confidence: 99%

Parametric optimization of electric field strength for cancer electrochemotherapy on a chip-based model

Zhao

Dong

et al. 2018

Theranostics

View full text Add to dashboard Cite

Electrochemotherapy (ECT), as one of the very few available treatments for cutaneous and subcutaneous tumors when surgery and radiotherapy are no longer available, requires applying a proper electric field to the tumor to realize electroporation-mediated cytotoxic drug delivery. It is impossible to exhaust all possible electrical parameters on patients to realize the optimal tradeoff between tumor suppression and adverse effects. To address this issue, this study provides a feasible solution by developing a four-leaf micro-electrode chip (F-MEC) in which the electric field was specially designed by linear distribution to cover all possible electric field strengths for ECT.Methods: We developed a F-MEC that provides a linearly varied electric field and a capacity for in situ observation of cell status. By culturing tumor cells on the F-MEC surface and in situ monitoring the cell responses to ECT drugs, the optimal electric field strength for any given cell type could be rapidly and accurately calculated in a few, or even only one, simple assay.Results: Using this chip, we monitored MCF-7 and A315 cell responses to ECT and determined the optimum ECT voltage. More importantly, we successfully verified that the in vitro determined voltage coincided with the optimal value for in vivo ECT in mice.Conclusion: In this proof-of-concept study, the in vivo tumor suppression assays proved that the optimal parameters acquired from in vitro F-MEC assay could be used for in vivo ECT.

show abstract

INV 12 Surgical approach on melanoma patients: an EORTC melanoma group survey

Cited by 7 publications

References 0 publications

Electrochemotherapy in Melanoma Patients: A Single Institution Experience

Electrochemotherapy in Melanoma Patients: A Single Institution Experience

Contrast‐Enhanced Ultrasound With Perflubutane for Sentinel Lymph Node Mapping in Cutaneous Melanoma: A Pilot Study

Parametric optimization of electric field strength for cancer electrochemotherapy on a chip-based model

Contact Info

Product

Resources

About